Tender detail
Conclusion of a non-exclusive medicines discount agreement for Bimekizumab for the period from 1 October 2026 to 31 March 2027
Summary
The tender concerns the conclusion of non-exclusive medicines discount agreements for medicines containing the active substance Bimekizumab (ATC L04AC21). The agreements are intended to run from 1 October 2026 to 31 March 2027, unless an exclusive agreement enters into force earlier. Interested pharmaceutical companies must identify the relevant medicines in Annex 2 to the agreement. The tender deadline is 29 January 2027.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.